Results 51 to 60 of about 65,280 (309)
Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel +12 more
wiley +1 more source
Background Healthcare costs in the U.S. are high and variable, which can hinder access and impact health outcomes across communities. This study examined hospital‐ and county‐level characteristics to identify factors that explain geographic variation in ...
Jennifer L. Moss +3 more
doaj +1 more source
Risk Factors for Hospital Malpractice Exposure: Implications for Managers and Insurers [PDF]
The possibility of identifying certain variables that might serve as predictors of above- or below-average medical malpractice claims experience was explored.
Katz, Patricia P. +2 more
core +1 more source
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert +6 more
wiley +1 more source
Some data on the participation of the engineer Samuel das Neves in Sâo Paulo's Improvements Plan. One of the outstanding professionals in São Paulo during the turn of the century was Bahia's agronomistengineer Samuel das Neves.
Maria Ruth Amaral de Sampaio
doaj
Background The phenomenon of growth in drug consumption within the framework of national volume-based procurement (VBP) policy raises speculations about demand release and policy inducing.
Ying Yang +7 more
doaj +1 more source
Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis +4 more
wiley +1 more source
ABSTRACT As the circular economy transition gains traction in the healthcare sector, extending the lifespan of complex medical devices has become a key priority, given their high cost and the challenges associated with their technological sophistication.
Tetiana Shevchenko +7 more
wiley +1 more source
Evaluating a Widely Implemented Proprietary Deterioration Index Model Among Hospitalized COVID-19 Patients [PDF]
ABSTRACT Introduction The Epic Deterioration Index (EDI) is a proprietary prediction model implemented in over 100 U.S. hospitals that was widely used to support medical decision-making during the COVID-19 pandemic.
Karandeep Singh +14 more
openaire +2 more sources
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary +59 more
wiley +1 more source

